JBPHF'
s PB Ratio Range Over the Past 10 Years
Min: 0.86 Med: 3.17 Max: 9.13
Current: 3.95
During the past 8 years, Jacobio Pharmaceuticals Group Co's highest PB Ratio was 9.13. The lowest was 0.86. And the median was 3.17.
JBPHF's PB Ratio is ranked worse than 63.23% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs JBPHF: 3.95
During the past 12 months, Jacobio Pharmaceuticals Group Co's average Book Value Per Share Growth Rate was -13.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -16.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -18.50% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Jacobio Pharmaceuticals Group Co was -16.50% per year. The lowest was -21.60% per year. And the median was -19.00% per year.
Back to Basics: PB Ratio
Jacobio Pharmaceuticals Group Co (OTCPK:JBPHF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Jacobio Pharmaceuticals Group Co PB Ratio Related Terms
Jacobio Pharmaceuticals Group Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobio Pharmaceuticals Group Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Jacobio Pharmaceuticals Group Co's PB Ratio falls into.
Jacobio Pharmaceuticals Group Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Jacobio Pharmaceuticals Group Co (JBPHF) has a PB Ratio of 6.24 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. This is 97% above median its historical median of 3.17. Over the past decade, Jacobio Pharmaceuticals Group Co's PB Ratio has ranged from 0.86 to 9.13. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #779 out of 1232 companies in the Biotechnology industry, placing it in the top 63.2%.
Is Jacobio Pharmaceuticals Group Co's PB Ratio too high?
Jacobio Pharmaceuticals Group Co's current PB Ratio of 6.24 is 97% above median its 10-year median of 3.17. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 9.13. The Biotechnology industry median PB Ratio is 2.80. Jacobio Pharmaceuticals Group Co's value of 6.24 is 122.9% above this industry median. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #779 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #779 out of 1232 companies for PB Ratio. This places Jacobio Pharmaceuticals Group Co in the lower half of its industry. The industry median PB Ratio is 2.80. Jacobio Pharmaceuticals Group Co's value of 6.24 is 122.9% above this benchmark. Historically, Jacobio Pharmaceuticals Group Co's own PB Ratio has ranged from 0.86 to 9.13 over the past decade. While the company's 10-year median is 3.17 vs. the industry median of 2.80, Jacobio Pharmaceuticals Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobio Pharmaceuticals Group Co's current PB Ratio of 6.24 is 122.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobio Pharmaceuticals Group Co's current PB Ratio is 6.24, which is 97% above median its own 10-year median of 3.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current PB Ratio of 6.24. The stock's GF Value™ is $0.42, compared to a current price of $0.87 — trading 106.6% above its estimated fair value. The current PB Ratio is 6.24, which is 97% above median its 10-year median of 3.17 and 122.9% above the Biotechnology industry median of 2.80. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current PB Ratio is 6.24 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued.
The current stock price of $0.87 is trading 106.6% above its estimated GF Value™ of $0.42.
Key valuation signals for JBPHF:
PB Ratio: 6.24 (97% above median its 10-year median of 3.17)
GF Value™: $0.42 vs. price of $0.87 (106.6% above fair value)
Industry Position: 122.9% above the Biotechnology median (#779 of 1232)
No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobio Pharmaceuticals Group Co Business Description
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score
Get the complete analysis for JBPHF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JBPHF has been successfully added to your 
